Related Experiment Video
Updated: Jul 7, 2026
An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis
Published on: September 12, 2019
[Significance of cyclooxygenase-2 as a chemotherapeutic target in hepatocellular carcinoma]
M A Kern1, P Schirmacher, M Breinig
1Pathologisches Institut, Universitäitsklinikum Heidelberg.
Aims:
Hepatocellular carcinoma (HCC) is the fifth most common cancer and the third leading cause of cancer related mortality worldwide. The incidence is dramatically increasing and no effective systemic treatments are available accentuating the urgent need for novel treatment approaches. A growing body of evidence suggest that COX-2 signaling is implicated in carcinogenesis and this study was conducted to evaluate the potential of selective COX-2 inhibition for the treatment and prevention of HCCs.
Methods:
The significance of COX-2 inhibition in HCCs was investigated in vitro (HCC cell-lines), in vivo (xenotransplanted tumors in nude mice) and ex vivo (precission-cut tissue sclice-cultures). Apoptosis-signaling was analyzed by means of immunohistochemistry, Western Blot analyses, Caspase-assays, FACS analyses after Nicoletti-staining, death receptor FACS-analysis, determination of mitochondrial membrane potential, and siRNA knockdown of Mcl-1.
Results:
Selective COX-2 inhibition led to a marked tumor-specific growth inhibition of human HCCs in vitro, in vivo and ex vivo based on reduction of proliferation and induction of apoptosis. Both, the death receptor (extrinsic)-, as well as the mitochondrial (intrinsic)-apoptotic pathways were involved. COX-2 inhibition led to an increased surface expression of death receptors and a marked down-regulation of Mcl-1, followed by translocation of Bax to mitochondria and a consecutive release of cytochrome c. Of clinical importance, COX-2 inhibition acted synergistically with chemotherapeutic drugs in the induction of apoptosis whereas primary human-hepatocytes were not sensitized towards apoptosis.
Conclusion:
COX-2 inhibition offers therapeutic and preventive potential in HCC.
Insights
Selective cyclooxygenase-2 (COX-2) inhibition effectively inhibits hepatocellular carcinoma (HCC) growth by inducing apoptosis. This approach shows therapeutic and preventive potential for HCC, even synergizing with chemotherapy.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Research
Background:
- Hepatocellular carcinoma (HCC) is a leading cause of cancer mortality with limited effective treatments.
- Cyclooxygenase-2 (COX-2) signaling is increasingly recognized for its role in cancer development.
- Novel therapeutic strategies are urgently needed for HCC treatment and prevention.
Purpose of the Study:
- To evaluate the therapeutic and preventive potential of selective COX-2 inhibition in hepatocellular carcinoma (HCC).
- To investigate the mechanisms underlying COX-2 inhibition's effects on HCC growth and survival.
Main Methods:
- In vitro (cell lines), in vivo (xenografts), and ex vivo (tissue slice cultures) models of HCC were used.
- Apoptosis signaling pathways were analyzed using immunohistochemistry, Western blot, caspase assays, and flow cytometry.
- Mitochondrial function and Mcl-1 expression were assessed, alongside siRNA knockdown studies.
Main Results:
- Selective COX-2 inhibition significantly reduced HCC tumor growth across all models by decreasing proliferation and inducing apoptosis.
- Both extrinsic (death receptor) and intrinsic (mitochondrial) apoptotic pathways were activated.
- COX-2 inhibition enhanced chemotherapy-induced apoptosis in HCC cells without sensitizing normal hepatocytes.
Conclusions:
- Selective COX-2 inhibition demonstrates significant therapeutic and preventive potential for hepatocellular carcinoma.
- The findings support COX-2 as a viable therapeutic target for HCC treatment.
More Related Videos
12:24A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma
Published on: September 30, 2021
07:25Development and Optimization of A Human Hepatocellular Carcinoma Patient-Derived Organoid Model for Potential Target Identification and Drug Discovery
Published on: August 18, 2023
Related Concept Videos
02:34Inhibition of Cdk Activity
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
02:15M-Cdk Drives Transition Into Mitosis
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
01:05Cancer-Critical Genes II: Tumor Suppressor Genes
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...